Carlos Paya V
Known title: DirectorCIK: 0001606244
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Transaction History
| PCVX | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 | View on chart |
| COLL | ▲ Buy | Grant | 8,741 | $0 | 5/14/2026 | View on chart |
| PCVX | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 | View on chart |
| COLL | ▲ Buy | Grant | 19,582 | $0 | 5/15/2025 | View on chart |
| PCVX | ▼ Sell | Gift | 2,500 | $0 | 12/6/2024 | View on chart |
| PCVX | ▲ Buy | Grant | 2,500 | $0 | 12/6/2024 | View on chart |
| PCVX | ▲ Buy | Grant | 1,550 | $0 | 6/6/2024 | View on chart |
| PCVX | ▼ Sell | Gift | 3,125 | $0 | 11/9/2023 | View on chart |
| PCVX | ▲ Buy | Grant | 3,125 | $0 | 11/9/2023 | View on chart |
| LAB | ▲ Buy | Grant | 26,376 | $0 | 6/14/2023 | View on chart |
| PCVX | ▲ Buy | Grant | 2,500 | $0 | 6/13/2023 | View on chart |
| LAB | ▲ Buy | Grant | 30,914 | $0 | 6/15/2022 | View on chart |
| PCVX | ▲ Buy | Grant | 3,125 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.